申请人:Hoffmann-La Roche Inc.
公开号:US04390540A1
公开(公告)日:1983-06-28
Imidazoquinazolines of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are hydrogen, halogen, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy or C.sub.2-5 -alkoxyalkyl; or two of R.sup.1, R.sup.2 and R.sup.3 on adjacent carbon atoms taken together are methylenedioxy or ethylenedioxy; and R.sup.4 and R.sup.5 are hydrogen or C.sub.1-4 -alkyl, and their tautomers, as well as their physiologically compatible acid addition salts, are described. The compounds of formula I inhibit the aggregation of the blood platelets, as well as gastric acid secretion, and have activity on the circulatory system.
公式为 ##STR1## 的咪唑喹啉类化合物,其中 R.sup.1、R.sup.2 和 R.sup.3 为氢、卤素、C.sub.1-4 -烷基、C.sub.1-4 -烷氧基或C.sub.2-5 -烷氧基烷基;或者 R.sup.1、R.sup.2 和 R.sup.3 中相邻碳原子上的两个共同为亚甲二氧基或乙二氧基;R.sup.4 和 R.sup.5 为氢或C.sub.1-4 -烷基,它们的互变异构体以及其生理相容性酸盐也被描述。公式 I 的化合物抑制血小板聚集,以及胃酸分泌,并对循环系统具有活性。